Search for: "Deas v. Deas" Results 1 - 20 of 579
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
14 Dec 2015, 3:36 pm by Sabrina I. Pacifici
EFF – “A Victory for Privacy and Transparency: HRW v. [read post]
22 Jul 2007, 5:23 pm
I took a step back, still in the V between the door and the car. [read post]
9 Mar 2015, 7:06 pm by FDABlog HPM
  The DEA Administrator should establish performance measures for DEA related to quotas and ensuring an adequate and uninterrupted supply of controlled substances for legitimate medical use. [read post]
24 Aug 2016, 8:26 pm by FDABlog HPM
Placement of a drug in one of the four schedules (II-V) where there has been a finding of accepted medical use relative to its potential for abuse and potential for psychological or physical dependence. [read post]
8 Oct 2010, 9:11 am by FDABlog HPM
An agent may telephone a pharmacy concerning a prescription for a controlled substance in schedules III through V and convey the practitioner’s otherwise valid oral prescription provided the prescriber has specified all required prescription information. 3. [read post]
8 Apr 2015, 7:04 am by Nate Cardozo
  Related Issues: InternationalSurveillance and Human RightsPrivacyRelated Cases: HRW v. [read post]
23 Jun 2012, 7:03 pm by W.F. Casey Ebsary, Jr.
Marijuana, versus Prescription Drugs, versus Meth, versus Heroin, versus Cocaine  DEA Chief grilled on impact of Marijuana, versus Prescription Drugs, versus Meth, versus Heroin, versus Cocaine. [read post]
14 Dec 2015, 12:21 pm by Mark Rumold
          Files: defendants_responses_to_plaintiffs_interrogatories_1-5.pdfletter_from_kathryn_wyer_to_mark_rumold.pdfRelated Issues: PrivacyRelated Cases: HRW v. [read post]
20 Dec 2012, 11:33 pm by FDABlog HPM
  HHS concluded that the scope and significance of the lorcaserin’s abuse potential is similar to schedule IV substances and its marketing as a schedule IV substance, rather than as an uncontrolled or schedule V substance, will decrease its potential for abuse. [read post]
4 Apr 2017, 1:18 am by FDABlog HPM
In a footnote, the Agency stated that “in DEA’s view,” this law does not apply to the reformulation of a drug containing a substance already controlled in Schedule II-V. [read post]
25 May 2015, 7:37 pm by FDABlog HPM
  Relying on the definition from the Supreme Court’s decision in Global-Tech Appliances, Inc. v. [read post]
4 Nov 2013, 7:54 pm by FDABlog HPM
  As evaluated by both HHS and DEA, data shows, however, that tramadol most closely compares to propoxyphene (Schedule IV) and codeine (Schedules II, III, and V). [read post]